| 2025-04-08 |
详情>>
股本变动：
变动后总股本16601.08万股
|
| 2025-04-08 |
详情>>
业绩披露：
2024年年报每股收益-0.34美元,归母净利润-948万美元,同比去年增长91.72%
|
| 2025-02-26 |
股东大会：
将于2025-03-28召开股东大会
会议内容 ▼▲
- 1.Authorize the slate of directors,
2.Authorize a reverse split of our common stock of 1:2 to 1:250,
3.Authorize a new Company Incentive Plan;
4.Ratify the appointment of Berkowitz Pollack Brant, CPAs as the Company’s independent registered public accounting firm for the year ended December 31, 2024;
5.The approval, on a non-binding advisory basis, of the frequency of future stockholder advisory votes to approve the compensation of our named executive officers;
6.Non-binding advisory vote on approval of compensation of our named executive officers.
|
| 2025-01-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.36美元,归母净利润-976.3万美元,同比去年增长90.00%
|
| 2024-12-23 |
详情>>
业绩披露：
2024年中报每股收益-0.15美元,归母净利润-423.5万美元,同比去年增长94.93%
|
| 2024-12-23 |
详情>>
业绩披露：
2024年一季报每股收益0.48美元,归母净利润1299.90万美元,同比去年增长118.03%
|
| 2024-11-25 |
详情>>
业绩披露：
2023年年报每股收益-4.35美元,归母净利润-1.14亿美元,同比去年增长-11843.07%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年一季报每股收益-2.9美元,归母净利润-7209.2万美元,同比去年增长-1241.25%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年中报每股收益-3.25美元,归母净利润-8352.3万美元,同比去年增长-557.25%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.76美元,归母净利润-9761万美元,同比去年增长-7032.73%
|
| 2024-03-07 |
复牌提示：
2024-03-07 09:50:05 停牌，复牌日期 2024-03-07 09:55:05
|
| 2023-08-04 |
股东大会：
将于2023-08-30召开股东大会
会议内容 ▼▲
- 1.To approve the Offering, which could result in the issuance of securities that will exceed 20% of our outstanding shares of common stock at a price less than the Minimum Price as defined by and in accordance with Nasdaq Listing Rule 5635(d) (the “Nasdaq Proposal”);
2.To approve to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Nasdaq Proposal (the “Adjournment Proposal”).
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-0.09美元,归母净利润-95.84万美元,同比去年增长-69.9%
|
| 2023-02-14 |
详情>>
内部人交易：
KATHURIA CHIRINJEEV共交易3笔
|
| 2023-01-12 |
股东大会：
将于2023-02-03召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an Agreement and Plan of Merger by and among AHAC, AHAC Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of AHAC (“Merger Sub”), Ocean Biomedical, Inc., a Delaware corporation (“Ocean Biomedical”), Aesther Healthcare Sponsor, LLC, (“Sponsor”) in its capacity as Purchaser Representative, and Dr. Chirinjeev Kathuria, in his capacity as Seller Representative that was amended on December 5, 2022 (as amended, the “Business Combination Agreement”), pursuant to which at the closing of the transactions contemplated by the Business Combination Agreement (the “Closing”), Merger Sub will merge with and into Ocean Biomedical (the “Merger”), with Ocean Biomedical continuing as the surviving corporation and wholly-owned subsidiary of AHAC. AHAC will change its name to Ocean Biomedical, Inc. at the Closing (collectively, the “Business Combination”). We refer to Ocean Biomedical, Inc. and its consolidated subsidiaries following the Business Combination as “New Ocean Biomedical.” A copy of the Business Combination Agreement is attached to the accompanying proxy statement as Annex A. We refer to this as the “Business Combination Proposal”;
2.To adopt and approve the Third Amended and Restated Certificate of Incorporation of AHAC, or the New Ocean Biomedical Charter, as set out in Annex B to this proxy statement, which shall become effective upon the Closing of the Business Combination (the “Charter Amendment Proposal”);
3.To consider and vote upon a proposal to approve, for purposes of complying with Nasdaq Listing Rules 5635(a) and (b), the issuance of more than 20% of the issued and outstanding Class A common stock and the resulting change in control in connection with the Business Combination (the “Nasdaq Proposal”);
4.To approve and adopt the 2022 Equity Incentive Plan, a copy of which is attached to the accompanying proxy statement as Annex C (the “Incentive Plan Proposal”);
5.To approve and adopt the Employee Stock Purchase Plan, a copy of which is attached to the accompanying proxy statement as Annex D (the “Employee Stock Purchase Plan Proposal”);
6.To consider and vote to elect eleven directors to serve staggered terms on AHAC’s board of directors until the 2023, 2024 and 2025 annual meeting of stockholders of AHAC, respectively, and until their respective successors are duly elected and qualified (the “Election of Directors Proposal”);
7.To adopt and approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation and vote of proxies if it is determined by AHAC that more time is necessary or appropriate to approve one or more Proposals at the Special Meeting (the “Adjournment Proposal”).
|
| 2022-10-17 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.52美元,归母净利润-136.85万美元,同比去年增长-3110.36%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|